GO
Loading...

Enter multiple symbols separated by commas

Merck & Co Inc

More

  • INTERVIEW-New-look GSK bets on consumer health spending Wednesday, 6 May 2015 | 7:19 AM ET

    LONDON, May 6- Consumers from New York to New Delhi are digging deeper in their pockets for over-the-counter remedies and health products, a trend GlaxoSmithKline is banking on to help shape the next chapter in its evolution. In the biggest shake-up in its 15- year history, GSK has just sold its cancer drugs to Novartis, while buying the Swiss group's vaccine...

  • April 29- Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new "focus area" will be subduing costs of a growing wave of pricey biotech cancer drugs. "This is going to be a much slower and much bigger effort over time than what you saw for hepatitis," Steve Miller, chief...

  • Investors on Fed statement, first-quarter GDP watch Wednesday, 29 Apr 2015 | 6:00 AM ET
    The Federal Reserve building in Washington.

    Investors will scrutinize US growth as the initial read on the first-quarter GDP comes ahead of a meeting statement from a 'data-dependent' Fed.

  • Asian equities retreat on lackluster earnings; Fed eyed Wednesday, 29 Apr 2015 | 3:30 AM ET

    Asian markets mostly fell on Wednesday as investors digested the raft of earnings due in the region and awaited the Federal Reserve's statement.

  • Investors on Fed watch as statement, GDP come out Tuesday, 28 Apr 2015 | 6:56 PM ET
    The Federal Reserve building in Washington.

    Investors will scrutinize US growth as the initial read on the first-quarter GDP comes ahead of a meeting statement from a 'data-dependent' Fed.

  • Pfizer Inc., Merck& Co. and Bristol-Myers Squibb Co., which reported first-quarter results Tuesday, all derive at least half their revenue from selling products overseas. Pfizer cut its 2015 earnings-per-share forecast by a nickel, to between $1.95 and $2.05, in the face of two fierce headwinds. New York- based Pfizer said those two factors will reduce 2015...

  • Traders work on the floor of the New York Stock Exchange.

    U.S.stocks closed mixed on Tuesday as investors eyed tech earnings and awaited the Federal Reserve's statement on Wednesday.

  • Most active New York Stock Exchange-traded stocks Tuesday, 28 Apr 2015 | 1:51 PM ET

    NEW YORK— A look at New York Stock Exchange 10 most-active stocks at the close of trading:. AK Steel Holding Corp. rose 9.4 percent to $5.35 with 22,809,400 shares traded. AT&T Inc. rose 2.3 percent to $34.86 with 48,346,300 shares traded.

  • Dollar hits Pfizer; Merck 'blew away' estimates Tuesday, 28 Apr 2015 | 9:04 AM ET
    Tablets of Pfizer Inc.'s Lipitor and Merck & Co.'s Zocor.

    Pfizer reported a 4 percent drop in quarterly revenue, while Merck posted earnings that topped expectations.

  • Janet Yellen speaking on March 18, 2015.

    U.S. stock index futures indicated a flat open on Tuesday ahead of the two-day FOMC meeting, housing data and a busy day of earnings.

  • April 28- Merck& Co's shares jumped almost 5 percent after the U.S. drugmaker reported better-than-expected quarterly results and released favorable data late Monday about the safety of its Januvia diabetes drug. The second-largest U.S. drugmaker on Tuesday said it earned $953 million, or 33 cents per share, in the first quarter. That compared with $1.71...

  • Innovation driving big pharma: Pro   Tuesday, 28 Apr 2015 | 8:09 AM ET
    Innovation driving big pharma: Pro

    Seamus Fernandez, Leerink Partners, and Barbara Ryan, Clermont Partners, share their thoughts on what's driving big pharma profits.

  • Merck 'blew away the quarter': Pro   Tuesday, 28 Apr 2015 | 8:05 AM ET
    Merck 'blew away the quarter': Pro

    Seamus Fernandez, Leerink Partners, and Barbara Ryan, Clermont Partners, break down the numbers on Pfizer's "ok" quarter, and Merck's "spectacular" results.

  • Early movers: BP, F, AAPL, BMY, COH, PFE & more Tuesday, 28 Apr 2015 | 8:01 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Cost-cutting and sales of new drugs helped Pfizer overcome a strong dollar and patent expirations to beat Wall Street projections for the first quarter, though it cut its outlook for the year, citing the unfavorable currency exchange rates. Most major drugmakers have overcome multibillion-dollar revenue hits from the unprecedented wave of patent...

  • Merck hurdles Wall Street forecasts Tuesday, 28 Apr 2015 | 7:18 AM ET

    Drugmaker Merck& Co. easily beat Wall Street expectations, sending its shares up sharply, despite first-quarter profit plunging 44 percent. While Merck's prescription drug sales jumped 16 percent in the U.S. in the quarter, they were down sharply in the huge Europe and Japan markets and some other regions. The world's fifth-biggest drugmaker said its net...

  • All eyes on Pfizer and Merck earnings   Tuesday, 28 Apr 2015 | 5:30 AM ET
    All eyes on Pfizer and Merck earnings

    Ranjith Gopinathan, program manager of life sciences and healthcare practice at Frost & Sullivan, shares his forecasts for Pfizer and Merck earnings.

  • Health care, Tesla top Halftime's trades to go Monday, 27 Apr 2015 | 2:49 PM ET

    The "Halftime Report" traders give their trades for the second half.

  • *FDA cites concerns over late-stage study design, results. April 27- U.S. Food and Drug Administration staff reviewers said an accelerated review of drugmaker Amgen Inc's skin cancer immunotherapy cannot be considered at this time, citing concerns over the design and results of a key study. T-Vec represents a new class of agent for the treatment of metastatic...

  • Why the S&P could break out this week Monday, 27 Apr 2015 | 7:12 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.